Clinical Trial Update: A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating imlunestrant with investigator's choice endocrine therapy and imlunestrant plus abemaciclib for ER-positive, HER2-negative advanced bre…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Abemaciclib (abemaciclib)
• Imlunestrant (imlunestrant)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Breast Neoplasms, Neoplasm Metastasis | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-07-11